(Q56442936)

primary sclerosing cholangitis

inferred from title

1 reference

inferred from title

author

Gideon M. Hirschfield

object named as

Gideon M Hirschfield

1

0 references

David Adams

object named as

David H Adams

4

0 references

Tom H Karlsen

2

object named as

Tom H Karlsen

0 references

author name string

Keith D Lindor

3

0 references

Gideon M Hirschfield

1

0 references

David H Adams

EASL Clinical Practice Guidelines: management of cholestatic liver diseases.

4

0 references

language of work or name

English

0 references

publication date

November 2013

0 references

9 November 2013

0 references

published in

The Lancet

0 references

volume

382

0 references

issue

9904

0 references

page(s)

1587-1599

0 references

1587-99

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Diagnosis and management of primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Mortality and the risk of malignancy in autoimmune liver diseases: A population-based study in Canterbury, New Zealand

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High lifetime risk of cancer in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Inflammatory disease of the bile ducts-cholangiopathies: liver biopsy challenge and clinicopathological correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Advances in cholangiocyte immunobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Genome-wide association analysis in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO⁻₃ output

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

CFTR dysfunction predisposes to fibrotic liver disease in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

CX(3)CR1 and vascular adhesion protein-1-dependent recruitment of CD16(+) monocytes across human liver sinusoidal endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

FXR and PXR: potential therapeutic targets in cholestasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Intestinal inflammation targets cancer-inducing activity of the microbiota.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Colonic mucosa-associated microbiota is influenced by an interaction of Crohn disease and FUT2 (Secretor) genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Identification of a novel antibody associated with autoimmune pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Functional anatomy of normal bile ducts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Sclerosing cholangitis in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Primary sclerosing cholangitis and disease distribution in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A unique clinical phenotype of primary sclerosing cholangitis associated with Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Cholangiocarcinoma and dominant strictures in patients with primary sclerosing cholangitis: a 25-year single-centre experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Primary sclerosing cholangitis: findings on cholangiography and pancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The Spectrum of Sclerosing Cholangitis and the Relevance of IgG4 Elevations in Routine Practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Primary sclerosing cholangitis associated with elevated immunoglobulin G4: clinical characteristics and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Cancer surveillance in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Diagnostic value of brush cytology in the diagnosis of bile duct carcinoma: a study in 65 patients with bile duct strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part II: multidisciplinary management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Diagnostic and therapeutic utility of single-operator peroral cholangioscopy for indeterminate biliary lesions and bile duct stones.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

In primary sclerosing cholangitis, gallbladder polyps are frequently malignant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Gallbladder disease in patients with primary sclerosing cholangitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Likelihood of malignancy in gallbladder polyps and outcomes following cholecystectomy in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The natural history of small-duct primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The predictors of the presence of varices in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Adenosine triphosphate release and purinergic (P2) receptor-mediated secretion in small and large mouse cholangiocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Oral budesonide in the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Tacrolimus for the treatment of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Intrabiliary rapamycin may slow progression of primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Complications after ERCP in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Selection of patients for liver transplantation and allocation of donated livers in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

A model to predict survival in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The TGR5 receptor mediates bile acid-induced itch and analgesia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021

Bone disease in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2960096-3

7 January 2021